Sanuwave Health, INC Form 4 insider transactions

SANUWAVE Health, Inc. reports that Director Jeffrey Blizard acquired stock options, indicating potential future equity participation.

Director Ian D. Miller of SANUWAVE Health, Inc. reported the acquisition of stock options.

Director James Tyler reported the acquisition of 5,524 stock options for SANUWAVE Health, Inc. (SNVW) with an exercise price of $10, exercisable from June 30, 2026, to June 30, 2031.

SANUWAVE Health, Inc. reports that CEO Morgan C. Frank acquired 5,524 stock options, fully vested at grant, with an exercise price of $10.

Opaleye Management Inc. reported the sale of 16,469 shares of SANUWAVE Health, Inc. common stock across multiple transactions.

Director James Tyler acquired stock options for 3,208 shares of SANUWAVE Health, Inc. under a Rule 10b5-1(c) plan.

SANUWAVE Health, Inc. CEO Morgan C. Frank reported the acquisition of stock options, indicating a vested interest in the company's performance.

Jeffrey Blizard, a Director at SANUWAVE Health, Inc., acquired stock options for 3,208 shares.

Director Gregory Bazar acquired 3,208 shares of common stock through the exercise of a stock option.

SEC Form 4 filing reveals Director Ian D. Miller acquired stock options for SANUWAVE Health, Inc. (SNVW).

SANUWAVE Health's Executive VP of Sales, David Timothy Wern, acquired 2,500 stock options with an exercise price of $26.96, vesting over three years.

SANUWAVE Health, Inc.'s CEO, Morgan C. Frank, was granted 24,000 stock options with an exercise price of $26.96, vesting quarterly throughout 2026.

SANUWAVE Health, Inc. CEO Morgan C. Frank acquired 1,540 stock options with an exercise price of $29.84, fully vested at grant.

SANUWAVE Health Director Ian D. Miller was granted 1,733 stock options, fully vested at grant, with an exercise price of $29.84.

SANUWAVE Health Director James Tyler acquired 1,540 stock options with an exercise price of $29.84, fully vested at grant, under a Rule 10b5-1 plan, effective December 31, 2025.

SANUWAVE Health, Inc. Director Gregory Matthew Bazar acquired 1,540 stock options, signaling confidence in the company's future.

SANUWAVE Health Director Jeffrey Blizard acquired 1,540 fully vested stock options with an exercise price of $29.84.

Key insiders associated with Manchester Management and James E. Besser reported sales of SANUWAVE Health, Inc. common stock totaling 20,000 shares.

An amended SEC Form 4/A reveals multiple insider stock sales by Manchester Management entities and individuals affiliated with SANUWAVE Health, totaling over 144,000 shares.

Multiple reporting persons associated with SANUWAVE Health, Inc. disclosed sales of common stock totaling 144,810 shares in early December 2025.

Opaleye Management Inc., a 10% owner and director, purchased 1,267 shares of SANUWAVE Health common stock for approximately $30.28 per share.

SANUWAVE Health, Inc. CEO Morgan C. Frank acquired 1,342 stock options, fully vested at grant, with an exercise price of $37.48.

SANUWAVE Health, Inc. Director James Tyler reported the acquisition of 1,342 stock options, fully vested at grant, with an exercise price of $37.48.

SANUWAVE Health Director Gregory Bazar acquired 1,342 stock options with an exercise price of $37.48, fully vested at grant.

SANUWAVE Health, Inc. Director Jeffrey Blizard reported the future acquisition of 1,342 stock options, fully vested at grant on September 30, 2025, with an exercise price of $37.48.

SANUWAVE Health Director Ian D. Miller acquired 1,510 stock options with an exercise price of $37.48, fully vested at grant.

SANUWAVE Health, Inc. Director James Tyler has been granted 1,574 stock options, aligning his interests with shareholders.

Jeffrey Blizard, a Director at SANUWAVE Health, Inc., acquired 1,574 stock options with an exercise price of $32.86, fully vested on the grant date of June 30, 2025.

SANUWAVE Health, Inc. Director Gregory Matthew Bazar was granted 1,574 stock options, which were fully vested at the grant date, with an exercise price of $32.86.

SANUWAVE Health, Inc. Director Ian D. Miller acquired 1,771 stock options with an exercise price of $32.86, which were fully vested upon grant.